William Blair
http://www.williamblair.comWilliam Blair & Company, L.L.C. is a Chicago-based investment firm offering investment banking, asset management, equity research, institutional and private brokerage, and private capital to individual, institutional, and issuing clients. Since 1935, it has been committed to helping clients achieve their financial objectives.
View Older Stories View More Recent Stories
-
William Blair Downgrades LegalZoom.com Inc (LZ) to Market Perform
-
William Blair Positive on Axon Enterprise (AXON): 'ARR Shows Acceleration to 39% Growth Supported by 41% FCB Growth'
-
Form 497 William Blair ETF Trust
-
Kforce Inc. to Participate in the William Blair Human Capital Services Virtual Conference
-
William Blair on Circle Internet Group (CRCL): 'Leaders Lead'
-
William Blair Downgrades Suja Life Inc. (SUJA) to Market Perform
-
Circle shares fall as revenue miss overshadows quarterly profit beat
-
William Blair Reiterates Outperform Rating on SpaceX (SPCX)
-
William Blair Downgrades Procept BioRobotics Corp (PRCT) to Market Perform
-
Twist Bioscience prices $300M public offering at $96 per share
-
Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock
-
Twist Bioscience proposes $250M common stock offering
-
Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock
-
SK Hynix rises as brokerages launch coverage with bullish ratings
-
William Blair on Palantir (PLTR): 'stellar performance defies concerns that competition with Anthropic and OpenAI is intensifying'
-
William Blair Starts SK Hynix (SKHY) at Outperform
-
William Blair Downgrades Lantheus Holdings (LNTH) to Market Perform
-
Obsidian Therapeutics completes Galera merger, raises $350M
-
Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million
-
William Blair Downgrades Birkenstock Holding plc (BIRK) to Market Perform
-
William Blair Adds GE Vernova (GEV) to Conviction List
-
William Blair Updates Analyst Conviction List For August 2026
-
Jersey Mike's closes IPO at $23 per share on NYSE
-
Jersey Mike’s Announces Closing of Initial Public Offering
-
Coinbase shares take hit on quarterly loss, analysts back diversification strategy
-
AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates
-
William Blair Reiterates Outperform Rating on SPX Technologies (SPXC)
-
Perimeter Solutions Reports Second Quarter 2026 Financial Results
-
William Blair Downgrades GoDaddy Inc (GDDY) to Market Perform
-
Jersey Mike's prices IPO at $23 per share on NYSE as JMKE
-
Jersey Mike’s Announces Pricing of Its Initial Public Offering
-
Reformation prices IPO at $15 per share on NYSE
-
Reformation Announces Pricing of Initial Public Offering
-
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
-
William Blair on Parsons Corp. (PSN): 'Guidance Cut on Program Write-Downs'
-
William Blair on Lennox International (LII): 'Our initial view is negative'
-
CAIS Welcomes New Strategic Investors, Valuing the Company at Over $2 Billion
-
William Blair Downgrades CoStar Group (CSGP) to Market Perform
-
William Blair Starts Rapport Therapeutics (RAPP) at Outperform
-
William Blair Starts Neutron Holdings (LIME) at Outperform
-
Form D William Blair PWM Opport
-
William Blair Reiterates Market Perform Rating on AMD (AMD)
-
William Blair Starts Mama’s Creations (MAMA) at Outperform
-
Lyntris files for IPO, plans to list on NYSE under "LYNX"
-
Lyntris Inc. Announces Filing of Registration Statement for Proposed Initial Public Offering
-
William Blair Starts Core & Main Inc. (CNM) at Market Perform
-
William Blair Downgrades Pegasystems (PEGA) to Market Perform
-
Repligen beefs up cell therapy business with $1.5 billion deal for BioLife
-
GE Vernova misses core profit estimates as Wind weakness persists
-
Many US patients opt for obesity drug injections, defying some expectations

